Year: 2022
Type: preprint
Abstract: Immune checkpoint inhibitors (ICI) are mostly used for melanoma treatment, however, the efficacy is achieved not for every patient. The cause of therapy failure can be explained by local immune suppression, which might be induced by different cytokines, including IL-1β. IL-1β is difficult to detect in peripheral blood, meanwhile, the high concentrations of IL-8 are frequently reported. IL-8 production is known to be induced by IL-1β in many cell types, however, there is no data on melanoma cells. This study aims to determine the relationship between IL-1β and IL-8 in patients with metastatic (mts) melanoma and assess the effect of IL-1β on IL-8 production by melanoma cells in vitro. The study involved 28 patients (pts) with mts melanoma taking ICI. The level of IL-1β and IL-8 in blood serum was determined using the ELISA method. In the experiments SK-MEL cells were incubated with/without IL-1β (1-1-2-4 ng/ml) for 9 days, every 2 days the cell media was collected. According to the study, with an IL-8 concentration of more than 42.31 pg/ml in patients with mts melanoma, the presence of IL-1β in the blood serum can be expected. At the same time, the level of IL-8 correlated with the level of IL-1β. The study also showed a concentration-dependent increase in the production of IL-1β and IL-8 by human melanoma cells with external exposure to IL-1β. The data obtained can allow us to assume, that high expression of IL-1β contributes to IL-8 production in tumor microenvironment (TME), which can be observed in peripheral blood and serve as a biomarker of high IL-1β expression in TME and local immune suppression. A high IL-8 level might be associated with a low ICI efficacy, but it`s needed to be studied in the following research.
Source: Research Square
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4220936660